Notably, patients benefited from pembrolizumab regardless of whether they achieved a pathologic complete response (pCR), ...
Despite meeting the primary endpoint in a Phase III study, two patients treated with Merck and Daiichi Sankyo’s experimental ...
A phase 3 trial of Daiichi Sankyo and Merck & Co.’s HER3-directed antibody-drug conjugate (ADC) has hit its primary endpoint, ...
Patients with locally advanced cervical cancer were randomized to receive either pembrolizumab or placebo in combination with ...
At ESMO, Multiple Enhertu Studies Highlight Challenges of Selecting, Managing Breast Cancer Patients
Researchers explored HER2 testing discordance, biomarkers of response, patient-reported outcomes, and the risk of lung-related disease.
Grivas disclosed relationships (including institutional funding) with Aadi Bioscience, Abbvie, Acrivon Therapeutics, ALX Oncology, AstraZeneca, Asieris Pharmaceuticals, Astellas, Bicycle Therapeutics, ...
Atezolizumab following vemurafenib and cobimetinib shows improved overall survival in BRAF V600–positive melanoma, but not ...
Patients with HER2-positive advanced or metastatic breast cancer received trastuzumab deruxtecan every 3 weeks.
Initial results from dose escalation in the first-in-human phase 1 trial of DS-9606 suggest early promising clinical activity in patients with advance ...
The combination of ramucirumab with trifluridine/tipiracil failed to show improvements in overall survival vs TAS-102 alone ...
Belzutifan improved progression-free survival and objective response rate compared to everolimus in previously treated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback